Relapsed/Refractory%20Multiple%20Myeloma
Showing 26 - 50 of >10,000
Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)
Recruiting
- Multiple Myeloma
-
Beverly Hills, CaliforniaBeverly Hills Cancer Center
Dec 21, 2022
Relapsed/Refractory Multiple Myeloma Trial in Louisville, Boston (agenT-797)
Active, not recruiting
- Relapsed/Refractory Multiple Myeloma
-
Louisville, Kentucky
- +2 more
Oct 21, 2022
Relapsed/Refractory Multiple Myeloma Trial in Xi'an (LUCAR-B68 cells product)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- LUCAR-B68 cells product
-
Xi'an, Shaanxi, ChinaSecond Affiliated Hospital of Xi'an Jiaotong University
Aug 10, 2022
Multiple Myeloma Trial in New York (Iberdomide, Elotuzumab, Dexamethasone)
Recruiting
- Multiple Myeloma
- Iberdomide
- +2 more
-
New York, New YorkIcahn School of Medicine
Jan 20, 2023
Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))
Not yet recruiting
- Multiple Myeloma
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Jan 13, 2023
Medicine Called Elranatamab in People With Relapsed Refractory
Not yet recruiting
- Multiple Myeloma
- Elranatamab
- Standard of care
- (no location specified)
Jun 30, 2023
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)
Withdrawn
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Rapid Infusion Isatuximab
- (no location specified)
Jul 3, 2022
Multiple Myeloma, Relapse Multiple Myeloma Trial in Bethesda, Madison (Descartes-25)
Recruiting
- Multiple Myeloma
- Relapse Multiple Myeloma
-
Shreveport, Louisiana
- +3 more
Nov 4, 2022
Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Isatuximab
- +3 more
- (no location specified)
Feb 3, 2023
Patients With Relapsed/Refractory Multiple Myeloma
Not yet recruiting
- Relapsed and Refractory Multiple Myeloma (RRMM)
- Non-Interventional
- (no location specified)
Dec 21, 2022
Myeloma Multiple Trial (Off Drug Surveillance)
Not yet recruiting
- Myeloma Multiple
- Off Drug Surveillance
- (no location specified)
Jun 27, 2023
Multiple Myeloma Trial in New York (drug, biological, procedure)
Active, not recruiting
- Multiple Myeloma
- busulfan
- +4 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 3, 2023
Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
Chevy Chase, Maryland
- +10 more
Jan 12, 2023
Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)
Recruiting
- Multiple Myeloma
- Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Actinium Ac 225-DOTA-Daratumumab
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Multiple Myeloma Trial in Hackensack (Bortezomib)
Terminated
- Multiple Myeloma
-
Hackensack, New JerseyThe Cancer Center at Hackensack University Medical Center
Jun 24, 2022
Multiple Myeloma Trial in Nashville (Cevostamab, Tocilizumab)
Recruiting
- Multiple Myeloma
-
Nashville, TennesseeTennessee Onc., PLLC - SCRI
Sep 8, 2022
Multiple Myeloma Trial in Shanghai (GC012F injection)
Recruiting
- Multiple Myeloma
- GC012F injection
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Jul 23, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))
Withdrawn
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Elotuzumab, Selinexor, and Dexamethasone (ESd)
- (no location specified)
Apr 27, 2022
Multiple Myeloma, Primary Plasma Cell Leukemia Trial in Shanghai (Experimental: CAR-T cells Infusion)
Not yet recruiting
- Multiple Myeloma
- Primary Plasma Cell Leukemia
- Experimental: CAR-T cells Infusion
-
Shanghai, ChinaShanghai Changzheng Hospital
Apr 20, 2023
Multiple Myeloma, Immune System Diseases Trial in Chapel Hill (CAR138 T Cells)
Recruiting
- Multiple Myeloma
- Immune System Diseases
- CAR138 T Cells
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Jan 10, 2023
Relapsed/Refractory Multiple Myeloma Trial in United States (Belantamab mafodotin)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Belantamab mafodotin
-
Clayton, North Carolina
- +4 more
May 16, 2023
Multiple Myeloma Trial (Elranatamab (PF-06863135))
Temporarily not available
- Multiple Myeloma
- Elranatamab (PF-06863135)
- (no location specified)
Jul 15, 2022